News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2014
-
Dec 26, 2014
Contribution to the Personalized Healthcare for Melanoma
Approval for BRAF inhibitor, “Zelboraf®” and its Companion Diagnostic, “cobas® 4800 BRAF V600 Mutation Test.”
[PDF 119KB] -
Dec 25, 2014
Chugai Wins the First Instance of the
Patent Infringement Lawsuit for Oxarol® Ointment
[PDF 107KB] -
Dec 24, 2014
Participation in the Global Health Innovative Technology Fund
(GHIT Fund)
[PDF 120KB] -
Dec 19, 2014
Anti-Cancer Agent “Xeloda®”
Application for Approval of Additional Indication of “Postoperative Adjuvant Chemotherapy for Gastric Cancer”
[PDF 123KB] -
Dec 09, 2014
Complete Phase I Results of Chugai’s Bispecific Antibody "ACE910" Released at the American Society of Hematology Meeting
[PDF 155KB] -
Dec 01, 2014
“INNOVATION BEYOND IMAGINATION”
Creating value beyond our conventional ideas and expectations
[PDF 237KB] -
Nov 26, 2014
Personnel Changes
[PDF 140KB] -
Nov 07, 2014
Phase I Data of Chugai’s Bispecific Antibody "ACE910" to be Presented at The American Society of Hematology Meeting
[PDF 93KB] -
Oct 29, 2014
Supply Plan of "Tamiflu®" Anti-influenza Drug for the 2014-2015 Season
[PDF 143KB] -
Oct 17, 2014
Fulfilling the Philosophy of Para-Sports Aimed at “Increase of Vitality for Convivial Society”
- New Contents Released on the Chugai Website - [PDF 113KB] -
Oct 16, 2014
F. Hoffmann-La Roche Announces Third Quarter Sales 2014
[PDF 76KB] -
Oct 01, 2014
Chugai to Join “BioJapan2014” as an Official Sponsor
The Largest Biotechnology Partnering Event in Asia
[PDF 340KB] -
Sep 25, 2014
Chugai Receives Two Awards in
“Commendation of Companies Promoting Gender Equality and Work-Family Balance 2014”
Hosted by the Ministry of Health, Labour and Welfare
[PDF 217KB] -
Sep 22, 2014
Bisphosphonate Antiresorptive Agent,
Ibandronate Sodium Hydrate Oral Agent,
Demonstrates Efficacy in Osteoporosis in Phase III Trial
[PDF 21KB] -
Sep 19, 2014
Chugai Debuts on Dow Jones Sustainability Asia Pacific Index,
an Index for Socially Responsible Investment
[PDF 189KB] -
Sep 08, 2014
Roche’s RoACTEMRA Receives EU Approval for Use in Patients
with Early Rheumatoid Arthritis (RA)
[PDF 237KB] -
Sep 08, 2014
30th Contribution of Para-transit Vehicles to Welfare Services
A Total of 203 Vehicles will be Donated
[PDF 224KB] -
Sep 05, 2014
Launch of the Anti-Cancer Agent / ALK Inhibitor “Alecensa®”
[PDF 199KB] -
Aug 29, 2014
Results of Japanese Phase II Clinical Trial for
Non-Small Cell Lung Cancer with EGFR Mutations was
Published Online on “The Lancet Oncology”
[PDF 181KB] -
Aug 28, 2014
Amendment of Business Arrangements Regarding
the Conditions for Out-Licensing Chugai Products
Based on the Strategic Alliance between Chugai and Roche
[PDF 178KB] -
Aug 27, 2014
Disclosure of Information on Chugai’s 2013 Corporate Activities
Based on Transparency Guidelines
[PDF 176KB] -
Aug 16, 2014
Regarding a Certain Media Report
[PDF 16KB] -
Jul 24, 2014
Organizational and Personnel Changes
[PDF 200KB] -
Jul 24, 2014
F. Hoffmann-La Roche Announces Half Year Results 2014
[PDF 21KB] -
Jul 17, 2014
Helsinn Group and Chugai Pharma Marketing Enter into Agreement for
Marketing Rights of Netupitant-Palonosetron Fixed-Dose Combination
(NEPA) in The UK and Ireland and for Palonosetron Monotherapy in The UK
[PDF 54KB] -
Jul 15, 2014
PharmaMar and Chugai Pharma Marketing Enter into a License and
Commercialization Agreement in Europe for Aplidin®
[PDF 58KB] -
Jul 04, 2014
An Anti-Cancer Agent, ALK Inhibitor “Alecensa®,”
Approved for the Treatment of ALK Fusion Gene Positive
Unresectable, Recurrent / Advanced Non-Small Cell Lung Cancer
[PDF 183KB] -
Jul 02, 2014
“Along with Antibody Drugs” — A Movie Newly Posted on Chugai’s
Website, Including Easy-to-understand Information on Antibody
Engineering Technologies as Chugai’s Strength
[PDF 311KB] -
Jun 13, 2014
Chugai Offers Biology Laboratory Class
for Elementary School Students
[PDF 234KB] -
May 23, 2014
Chugai and Roche Enter a License Agreement for
Chugai’s Proprietary Innovative Antibody Engineering Technologies
[PDF 207KB] -
May 12, 2014
Determination of Terms and Conditions of Stock Options
(Stock Acquisition Rights)
[PDF 36KB] -
Apr 28, 2014
Roche Receives EU Approval for New Subcutaneous
Formulation of RoACTEMRA
Providing more Treatment Flexibility
for Patients with Moderate to Severe Rheumatoid Arthritis
[PDF 200KB] -
Apr 25, 2014
Chugai Pharma USA Announces Appointment of
Chief Medical Officer
[PDF 180KB] -
Apr 24, 2014
Issuance of Stock Options (Stock Acquisition Rights)
[PDF 76KB] -
Apr 17, 2014
Launch of the Anti-Cancer Agent “Kadcyla®”
[PDF 214KB] -
Apr 15, 2014
F. Hoffmann-La Roche Announces First Quarter Sales 2014
[PDF 21KB] -
Apr 09, 2014
New Drug Application Filed for “Vemurafenib”
for the Treatment of Melanoma with BRAFV600 Mutation
and a Companion Diagnostic to Detect the BRAF Mutation
[PDF 64KB] -
Mar 20, 2014
Chugai to Participate in
High-Quality Protein Crystal Growth Experiment
in the International Space Station, “Kibo,” as Private Company
[PDF 214KB] -
Feb 10, 2014
Chugai Won the Award for Excellence
in the 16th Nikkei Annual Report Awards
[PDF 190KB] -
Jan 30, 2014
Personnel Changes
[PDF 130KB] -
Jan 30, 2014
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2013
[PDF 45KB]